IT 139

Drug Profile

IT 139

Alternative Names: IT-139; KP-1339; NKP-1339

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Vienna
  • Developer Intezyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors; JNK mitogen-activated protein kinase inhibitors; Molecular chaperone GRP78 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Nov 2017 Intezyne plans a phase Ib/IIa trial of IT 139 for solid tumours (Combination therapy) in mid 2018
  • 15 Nov 2017 IT 139 is available for licensing as of 15 Nov 2017.
  • 10 Oct 2017 9224246: financing info
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top